{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:34:59Z","timestamp":1795174499548,"version":"4.10.3"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>ICUs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>\n                      Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 45 and\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 60, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>IV angiotensin II or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results:<\/jats:title>\n                    <jats:p>\n                      Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of \u2265 10\u2009mm Hg or increase to \u2265 75\u2009mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%\u201367%) and 30% (95% CI, 19%\u201341%) in patients treated with angiotensin II and placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.012), respectively. By day 7, 38% (95% CI, 25%\u201354%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%\u201327%) placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%\u201368%) and 22% (95% CI, 12%\u201334%) of patients treated with angiotensin II and placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.001), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ccm.0000000000003092","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T04:23:06Z","timestamp":1520310186000},"page":"949-957","source":"Crossref","is-referenced-by-count":278,"title":["Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II"],"prefix":"10.1097","volume":"46","author":[{"given":"James A.","family":"Tumlin","sequence":"first","affiliation":[{"name":"University of Tennessee College of Medicine, Chattanooga TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavan","family":"Murugan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, and Clinical and Translational Science, Center for Critical Care Nephrology, CRISMA, University of Pittsburgh School of Medicine, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Deane","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Royal Melbourne Hospital, University of Melbourne, Grattan St, Parkville, Victoria, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ostermann","sequence":"additional","affiliation":[{"name":"King\u2019s College London, Guy\u2019s & St Thomas\u2019 Hospital, London, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence W.","family":"Busse","sequence":"additional","affiliation":[{"name":"Emory University, Department of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kealy R.","family":"Ham","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical School; Department Chair of Critical Care Medicine, Regions Hospital, Saint Paul, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kianoush","family":"Kashani","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold M.","family":"Szerlip","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Prowle","sequence":"additional","affiliation":[{"name":"Adult Critical Care Unit, Department of Renal and Transplant Medicine, The Royal London Hospital, London, UK; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Bihorac","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension, & Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Finkel","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at Houston, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zarbock","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital M\u00fcnster, M\u00fcnster, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lui G.","family":"Forni","sequence":"additional","affiliation":[{"name":"Department of Clinical & Experimental Medicine, Faculty of Health Sciences, University of Surrey & Critical Care Unit, Royal Surrey County Hospital, Guildford, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan J.","family":"Lynch","sequence":"additional","affiliation":[{"name":"La Jolla Pharmaceutical Company."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Jensen","sequence":"additional","affiliation":[{"name":"La Jolla Pharmaceutical Company."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stew","family":"Kroll","sequence":"additional","affiliation":[{"name":"La Jolla Pharmaceutical Company."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhmir S.","family":"Chawla","sequence":"additional","affiliation":[{"name":"La Jolla Pharmaceutical Company."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Tidmarsh","sequence":"additional","affiliation":[{"name":"La Jolla Pharmaceutical Company."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[{"name":"The University of Melbourne, Melbourne, VIC, Australia; Austin Hospital, Heidelberg, VIC, Australia; Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia; Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230728","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMra1208943","article-title":"Circulatory shock.","volume":"369","author":"Vincent","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20230728","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"SOAP II Investigators: Comparison of dopamine and norepinephrine in the treatment of shock.","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMra002709","article-title":"The pathogenesis of vasodilatory shock.","volume":"345","author":"Landry","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-20230728","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute Disease Quality Initiative Workgroup 16: Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"R5-20230728","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00134-017-4832-y","article-title":"Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.","volume":"43","author":"Joannidis","year":"2017","journal-title":"Intensive Care Med"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2010050484","article-title":"Sepsis and acute kidney injury.","volume":"22","author":"Zarjou","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients a multinational, multicenter study.","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes.","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1603017","article-title":"AKIKI Study Group: Initiation strategies for renal-replacement therapy in the intensive care unit.","volume":"375","author":"Gaudry","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.2016.5828","article-title":"Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial.","volume":"315","author":"Zarbock","year":"2016","journal-title":"JAMA"},{"key":"R11-20230728","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1620\/tjem.238.17","article-title":"Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury.","volume":"238","author":"Lim","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/cc6823","article-title":"The histopathology of septic acute kidney injury: a systematic review.","volume":"12","author":"Langenberg","year":"2008","journal-title":"Crit Care"},{"key":"R13-20230728","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI200422353","article-title":"Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.","volume":"114","author":"Schrier","year":"2004","journal-title":"J Clin Invest"},{"key":"R14-20230728","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semnephrol.2015.01.007","article-title":"Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation.","volume":"35","author":"Prowle","year":"2015","journal-title":"Semin Nephrol"},{"key":"R15-20230728","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.01820407","article-title":"Approach to hemodynamic shock and vasopressors.","volume":"3","author":"Herget-Rosenthal","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-20230728","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.kint.2016.02.017","article-title":"Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury.","volume":"90","author":"Lankadeva","year":"2016","journal-title":"Kidney Int"},{"key":"R17-20230728","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMra064398","article-title":"Normotensive ischemic acute renal failure.","volume":"357","author":"Abuelo","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-20230728","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/cc8185","article-title":"Angiotensin II in experimental hyperdynamic sepsis.","volume":"13","author":"Wan","year":"2009","journal-title":"Crit Care"},{"key":"R19-20230728","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"ATHOS-3 Investigators: Angiotensin II for the treatment of vasodilatory shock.","volume":"337","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20230728","first-page":"43","article-title":"Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.","volume":"19","author":"Chawla","year":"2017","journal-title":"Crit Care Resusc"},{"key":"R21-20230728","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13613-015-0085-5","article-title":"Personalizing blood pressure management in septic shock.","volume":"5","author":"Kato","year":"2015","journal-title":"Ann. Intensive Care"},{"key":"R22-20230728","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13054-017-1896-6","article-title":"The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.","volume":"21","author":"Busse","year":"2017","journal-title":"Crit Care"},{"key":"R23-20230728","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/adc.82.5.388","article-title":"Angiotensin for septic shock unresponsive to noradrenaline.","volume":"82","author":"Yunge","year":"2000","journal-title":"Arch Dis Child"},{"key":"R24-20230728","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0140-6736(95)91933-3","article-title":"Severe septic shock unresponsive to noradrenaline.","volume":"346","author":"Wray","year":"1995","journal-title":"Lancet"},{"key":"R25-20230728","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/00003246-199108000-00020","article-title":"Administration of angiotensin II in refractory septic shock.","volume":"19","author":"Thomas","year":"1991","journal-title":"Crit Care Med"},{"key":"R26-20230728","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1161\/01.CIR.102.16.2011","article-title":"Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.","volume":"102","author":"Orfanos","year":"2000","journal-title":"Circulation"},{"key":"R27-20230728","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/CCM.0000000000002797","article-title":"Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury.","volume":"46","author":"Lankadeva","year":"2018","journal-title":"Crit Care Med"},{"key":"R28-20230728","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1378\/chest.98.1.170","article-title":"Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter.","volume":"98","author":"Brenner","year":"1990","journal-title":"Chest"},{"key":"R29-20230728","doi-asserted-by":"crossref","first-page":"R1226","DOI":"10.1152\/ajpregu.00228.2015","article-title":"Variable responses of regional renal oxygenation and perfusion to vasoactive agents in awake sheep.","volume":"309","author":"Calzavacca","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R30-20230728","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury.","volume":"121","author":"Bonventre","year":"2011","journal-title":"J Clin Invest"},{"key":"R31-20230728","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00134-012-2487-2","article-title":"Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion.","volume":"38","author":"May","year":"2012","journal-title":"Intensive Care Med"},{"key":"R32-20230728","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/CCM.0b013e318218665a","article-title":"Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock.","volume":"39","author":"Nakada","year":"2011","journal-title":"Crit Care Med"},{"key":"R33-20230728","first-page":"6551","article-title":"Increased susceptibility of sepsis associated with CD143 deletion\/insertion polymorphism in Caucasians: a meta-analysis.","volume":"7","author":"Yang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"R34-20230728","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3892\/etm.2014.1566","article-title":"Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis.","volume":"7","author":"Zhang","year":"2014","journal-title":"Exp Ther Med"},{"key":"R35-20230728","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1097\/CCM.0b013e318186a299","article-title":"Angiotensin converting enzyme insertion\/deletion genetic polymorphism: its impact on renal function in critically ill patients.","volume":"36","author":"du Cheyron","year":"2008","journal-title":"Crit Care Med"},{"key":"R36-20230728","first-page":"0703","article-title":"Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II.","volume":"5","author":"Wunderink","year":"2017","journal-title":"Intensive Care Med Exp"},{"key":"R37-20230728","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.medin.2016.07.010","article-title":"Castellanos-Ortega A: Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.","volume":"41","author":"Suberviola","year":"2017","journal-title":"Med Intensiva"},{"key":"R38-20230728","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-015-0802-3","article-title":"Angiotensin II in septic shock.","volume":"19","author":"Corr\u00eaa","year":"2015","journal-title":"Crit Care"},{"key":"R39-20230728","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ekir.2017.06.020","article-title":"Novel therapies for acute kidney injury.","volume":"2","author":"Chen","year":"2017","journal-title":"Kidney Int Rep"},{"key":"R40-20230728","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13054-016-1306-5","article-title":"The use of angiotensin II in distributive shock.","volume":"20","author":"Chawla","year":"2016","journal-title":"Crit Care"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003246-201806000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:31:02Z","timestamp":1690522262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003246-201806000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000003092","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}